当前位置: X-MOL 学术Clin. Appl. Thromb. Hemost. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The Cost of Von Willebrand Disease in Europe: The CVESS Study
Clinical and Applied Thrombosis/Hemostasis ( IF 2.9 ) Pub Date : 2022-08-17 , DOI: 10.1177/10760296221120583
George Morgan 1 , Sarah Brighton 1 , Mike Laffan 2 , Jenny Goudemand 3 , Bethany Franks 1 , Alan Finnegan 4
Affiliation  

Background

Von Willebrand disease (VWD) is one of the most common inherited bleeding disorders, imposing a substantial health impact and financial burden. The Cost of von Willebrand disease in Europe: A Socioeconomic Study (CVESS) characterises the socio-economic cost of VWD across Germany, Spain, Italy, France, and the UK.

Methods

A retrospective, cross-sectional design captured 12 months of patient disease management, collected from August-December 2018, for 974 patients. This enabled estimation of direct medical, direct non-medical and indirect costs, utilising prevalence estimates to extrapolate to population level.

Results

Total annual direct medical cost (including/excluding von Willebrand factor [VWF]) across all countries was the highest cost (€2 845 510 345/€444 446 023), followed by indirect costs (€367 330 271) and direct non-medical costs (€60 223 234). Differences were seen between countries: the UK had the highest direct medical costs excluding VWF (€159 791 064), Italy the highest direct-non medical (€26 564 496), and Germany the highest indirect cost burden (€197 036 052). Total direct medical costs per adult patient increased across VWD types with Type 1 having the lowest cost (€23 287) and Type 3 having the highest cost (€133 518).

Conclusion

A substantial financial burden arises from the prevalence of VWD for the European healthcare systems considered.



中文翻译:

欧洲冯维勒布兰德病的成本:CVESS 研究

背景

冯维勒布兰德病 (VWD) 是最常见的遗传性出血性疾病之一,对健康造成重大影响和经济负担。欧洲Willebrand病的成本:一项社会经济研究( CVESS )描述了德国、西班牙、意大利、法国和英国的 VWD 的社会经济成本。

方法

一项回顾性横断面设计捕获了 12 个月的患者疾病管理,从 2018 年 8 月至 12 月收集了 974 名患者。这使得能够估计直接医疗、直接非医疗和间接成本,利用流行率估计来推断人口水平。

结果

所有国家/地区的年度直接医疗总成本(包括/不包括冯维勒布兰德因子 [VWF])最高(2 845 510 345 欧元/444 446 023 欧元),其次是间接成本(367 330 271 欧元)和直接非医疗费用(60 223 234 欧元)。各国之间存在差异:英国的直接医疗费用最高,不包括 VWF(159 791 064 欧元),意大利的直接非医疗费用最高(26 564 496 欧元),德国的间接成本负担最高(197 036 052 欧元) . 每个成年患者的直接医疗总成本在 VWD 类型中有所增加,其中 1 型成本最低(23287 欧元),3 型成本最高(133518 欧元)。

结论

在所考虑的欧洲医疗保健系统中,VWD 的普遍存在造成了巨大的经济负担。

更新日期:2022-08-18
down
wechat
bug